Literature DB >> 2811474

Activated human blood monocytes trigger the antitumor activity of blood polymorphonuclear cells.

I J Fidler1, A Nii, J Y Tsao, S Davis, E S Kleinerman.   

Abstract

The purpose of these studies was to determine whether human peripheral blood polymorphonuclear cells (PMNC) can be directly activated by lymphokines or bacterial products to lyse tumorigenic cells under in vitro conditions. Preparations of PMNC with different levels of purity were isolated by countercurrent elutriation. PMNC were incubated with recombinant interferon gamma and muramyldipeptide, with lipopolysaccharide, or with the synthetic lipopeptide CGP 31362. Only PMNC preparations containing 3-5% mononuclear cells lysed allogeneic melanoma cells. Homogeneous populations of PMNC did not. The addition of 5% monocytes to homogeneous populations of PMNC triggered PMNC-mediated tumor lysis. Cell-to-cell contact was not required in this process since culture supernatant of blood monocytes incubated with lipopolysaccharide (but not with medium) could trigger tumor cell lysis by PMNC. PMNC lysed both allogeneic tumorigenic (melanoma) and allogeneic nontumorigenic (fibroblast) cells, whereas activated monocytes lysed only tumorigenic cells. In conclusion, PMNC are triggered to lyse target cells by blood monocytes activated by bacterial products or by lymphokines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811474

Source DB:  PubMed          Journal:  Lymphokine Res        ISSN: 0277-6766


  3 in total

1.  Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.

Authors:  C Schneider; T Schmidt; C Ziske; K Tiemann; K-M Lee; V Uhlinsky; P Behrens; T Sauerbruch; I G H Schmidt-Wolf; P F Mühlradt; J Schmidt; A Märten
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

2.  Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

Authors:  M Saito; D Fan; L B Lachman
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

3.  Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.

Authors:  J Schmidt; T Welsch; D Jäger; P F Mühlradt; M W Büchler; A Märten
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.